Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ziltivekimab, an antibody targeting IL6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tifcemalimab, an antibody targeting BTLA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sasanlimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rosopatamab, an antibody targeting PSMA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Feladilimab, an antibody targeting ICOS.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tozorakimab, an antibody targeting IL-33.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sibeprenlimab, an antibody targeting APRIL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mibavademab, an antibody targeting LEPR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lusvertikimab, an antibody targeting IL-7R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lemzoparlimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Latozinemab, an antibody targeting Sortilin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Imsidolimab, an antibody targeting IL-36R.